Seismic Therapeutic

Seismic Therapeutic, a biotechnology company founded in 2020, has positioned itself as "The Machine Learning Immunology Company." Leveraging their IMPACT™ platform, the company integrates machine learning into every aspect of biologics drug discovery and development, focusing on structural biology, protein engineering, and translational immunology. This approach aims to create optimized therapies for patients. Seismic Therapeutic is making strides in addressing adaptive immune system dysregulation to treat autoimmune diseases, with an emerging pipeline of novel approaches. The company is headquartered in the biotechnology hub of Boston, United States. In its latest funding round, Seismic Therapeutic secured a substantial $121.00M in Series B investment on 4th December 2023. The investment came from an impressive consortium of life sciences investors including Bessemer Venture Partners, Gaingels, Lightspeed Venture Partners, Amgen Ventures, GV, Alexandria Venture Investments, Codon Capital, Samsara BioCapital, Timothy A. Springer, GC&H Investments. This strong financial backing positions Seismic Therapeutic for continued growth and innovation in the biotechnology and healthcare industries.